Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christoph Wanner

Showing results (211-220 of 785) with videos related to

Pageof 79
Sort By:
Nature Clinical Practice. Nephrology|April 24, 2008
Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adultsAlberto Ortiz, João P Oliveira, Christoph Wanner, et al.
American Journal of Nephrology|January 11, 2018
Long-Term Survivor Characteristics in Hemodialysis Patients with Type 2 DiabetesSusanne Triebswetter, Lena J Gutjahr-Lengsfeld, Kay-Renke Schmidt, et al.
Clinical Chemistry|March 25, 2005
Are glucokinase mutations associated with low triglycerides?Mario Berger, Detlev Mönks, Henriette Schmidt, et al.
Cardiovascular Ultrasound|September 17, 2020
Quantification of left ventricular mass by echocardiography compared to cardiac magnet resonance imaging in hemodialysis patientsSören Jendrik Grebe, Uwe Malzahn, Julian Donhauser, et al.
Journal of Renal Nutrition : the Official Journal of the Council on Renal Nutrition of the National Kidney Foundation|December 21, 2013
Time to revisit the role of renal dietitian in the dialysis unitT Alp Ikizler, Harold A Franch, Kamyar Kalantar-Zadeh, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 13, 2005
Optimal treatment of renal anaemia (OPTA): improving the efficacy and efficiency of renal anaemia therapy in haemodialysis patients receiving intravenous epoetinWalter H Hörl, Yves Vanrenterghem, Bernard Canaud, et al.
Molecular Genetics and Metabolism|May 5, 2018
Therapeutic goals in Fabry disease: Recommendations of a European expert panel, based on current clinical evidence with enzyme replacement therapyChristoph Wanner, Dominique P Germain, Max J Hilz, et al.
Advances in Therapy|May 21, 2024
Safety of Empagliflozin: An Individual Participant-Level Data Meta-Analysis from Four Large TrialsChristoph Wanner, Hristo Iliev, Nathalia Duarte, et al.
Molecular Genetics and Metabolism Reports|August 31, 2019
Response to Gurevich and colleagues: The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: a systematic literature review by a European panel of expertsDominique P Germain, Bruno Falissard, Max J Hilz, et al.
Kidney & Blood Pressure Research|December 2, 2006
Vasopeptidase inhibition normalizes blood pressure and restores endothelial function in renovascular hypertensionThomas Quaschning, Berthold Hocher, Sabine Ruhl, et al.
Pageof 79

Showing results (211-220 of 785) with videos related to

Sort By:
Pageof 79
Nature Clinical Practice. Nephrology|April 24, 2008
Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adultsAlberto Ortiz, João P Oliveira, Christoph Wanner, et al.
American Journal of Nephrology|January 11, 2018
Long-Term Survivor Characteristics in Hemodialysis Patients with Type 2 DiabetesSusanne Triebswetter, Lena J Gutjahr-Lengsfeld, Kay-Renke Schmidt, et al.
Clinical Chemistry|March 25, 2005
Are glucokinase mutations associated with low triglycerides?Mario Berger, Detlev Mönks, Henriette Schmidt, et al.
Cardiovascular Ultrasound|September 17, 2020
Quantification of left ventricular mass by echocardiography compared to cardiac magnet resonance imaging in hemodialysis patientsSören Jendrik Grebe, Uwe Malzahn, Julian Donhauser, et al.
Journal of Renal Nutrition : the Official Journal of the Council on Renal Nutrition of the National Kidney Foundation|December 21, 2013
Time to revisit the role of renal dietitian in the dialysis unitT Alp Ikizler, Harold A Franch, Kamyar Kalantar-Zadeh, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 13, 2005
Optimal treatment of renal anaemia (OPTA): improving the efficacy and efficiency of renal anaemia therapy in haemodialysis patients receiving intravenous epoetinWalter H Hörl, Yves Vanrenterghem, Bernard Canaud, et al.
Molecular Genetics and Metabolism|May 5, 2018
Therapeutic goals in Fabry disease: Recommendations of a European expert panel, based on current clinical evidence with enzyme replacement therapyChristoph Wanner, Dominique P Germain, Max J Hilz, et al.
Advances in Therapy|May 21, 2024
Safety of Empagliflozin: An Individual Participant-Level Data Meta-Analysis from Four Large TrialsChristoph Wanner, Hristo Iliev, Nathalia Duarte, et al.
Molecular Genetics and Metabolism Reports|August 31, 2019
Response to Gurevich and colleagues: The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: a systematic literature review by a European panel of expertsDominique P Germain, Bruno Falissard, Max J Hilz, et al.
Kidney & Blood Pressure Research|December 2, 2006
Vasopeptidase inhibition normalizes blood pressure and restores endothelial function in renovascular hypertensionThomas Quaschning, Berthold Hocher, Sabine Ruhl, et al.
Pageof 79